Načítá se...
Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer’s and Parkinson’s disease therapeutics
Among the more promising treatments proposed for Alzheimer’s disease (AD) and Parkinson’s disease (PD) are those reducing brain insulin resistance. The antidiabetics in the class of incretin receptor agonists (IRAs) reduce symptoms and brain pathology in animal models of AD and PD, as well as glucos...
Uloženo v:
| Vydáno v: | Biochem Pharmacol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7606641/ https://ncbi.nlm.nih.gov/pubmed/32755557 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2020.114187 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|